TREG-cell therapies for autoimmune rheumatic diseases

Nature Reviews Rheumatology

Volumn 10, Issue 9, 2014, Pages 543-551

  Miyara, Makoto ^a   Ito, Yoshinaga ^b   Sakaguchi, Shimon ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b KYOTO UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CD4 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; RETINOIC ACID; TRANSCRIPTION FACTOR FOXP3;

ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL EXPANSION; CELL SURVIVAL; CELL THERAPY; COLLAGEN-INDUCED ARTHRITIS; CYTOLOGY; EFFECTOR CELL; EX VIVO STUDY; EXPERIMENTAL ARTHRITIS; FOXP3+ CD25+ CD4+ REGULATORY T LYMPHOCYTE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; ONTOGENY; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOGLYCAN-INDUCED ARTHRITIS; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; VASCULITIS; ANIMAL; DISEASE MODEL;

ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; HUMANS; RHEUMATIC DISEASES; T-LYMPHOCYTES, REGULATORY;

EID: 84908089142     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2014.105     Document Type: Review

References (133)

1. Sakaguchi, S., Yamaguchi, T., Nomura, T. & Ono, M. Regulatory T cells and immune tolerance. Cell 133, 775-787 (2008).
2. Lahl, K. et al. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J. Exp. Med. 204, 57-63 (2007).
3. Kim, J. M., Rasmussen, J. P. & Rudensky, A. Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8, 191-197 (2007).
4. Fontenot, J. D., Gavin, M. A. & Rudensky, A. Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4, 330-336 (2003).
5. Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057-1061 (2003).
6. Khattri, R., Cox, T., Yasayko, S. A. & Ramsdell, F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. 4, 337-342 (2003).
7. Wildin, R. S. & Freitas, A. IPEX and FOXP3: Clinical and research perspectives. J. Autoimmun. 25 (Suppl.), 56-62 (2005).
8. Feuerer, M. et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 15, 930-939 (2009).
9. Tse, K., Tse, H., Sidney, J., Sette, A. & Ley, K. T cells in atherosclerosis. Int. Immunol. 25, 615-622 (2013).
10. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor a-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151-1164 (1995).
11. Miyara, M. et al. Human Foxp3+ regulatory T cells in systemic autoimmune diseases. Autoimmun. Rev. 10, 744-755 (2011).
12. de Lafaille, M. A. C., Lino, A. C., Kutchukhidze, N. & Lafaille, J. J. CD25-T cells generate CD25+Foxp3+ regulatory T cells by peripheral expansion. J. Immunol. 173, 7259-7268 (2004).
13. Fantini, M. C. et al. Cutting edge: TGF-β induces a regulatory phenotype in CD4+CD25-T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 172, 5149-5153 (2004).
14. Fu, S. et al. TGF-β induces Foxp3+T-regulatory cells from CD4+CD25-precursors. Am. J. Transplant. 4, 1614-1627 (2004).
15. Zheng, S. G., Wang, J. H., Gray, J. D., Soucier, H. & Horwitz, D. A. Natural and induced CD4+CD25+ cells educate CD4+CD25-cells to develop suppressive activity: The role of IL-2, TGF-β, and IL-10. J. Immunol. 172, 5213-5221 (2004).
16. Liang, S. et al. Conversion of CD4+ CD25-cells into CD4+ CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus. J. Exp. Med. 201, 127-137 (2005).
17. Thornton, A. M. et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J. Immunol. 184, 3433-3441 (2010).
18. Yadav, M. et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J. Exp. Med. 209, 1713-1722, S1-S19 (2012).
19. Weiss, J. M. et al. Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells. J. Exp. Med. 209, 1723-1742, S1 (2012).
20. Benson, M. J., Pino-Lagos, K., Rosemblatt, M. & Noelle, R. J. All-trans retinoic acid mediates enhanced TREG cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J. Exp. Med. 204, 1765-1774 (2007).
21. Coombes, J. L. et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-β-and retinoic acid-dependent mechanism. J. Exp. Med. 204, 1757-1764 (2007).
22. Denning, T. L., Wang, Y. C., Patel, S. R., Williams, I. R. & Pulendran, B. Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat. Immunol. 8, 1086-1094 (2007).
23. Sun, C. M. et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 TREG cells via retinoic acid. J. Exp. Med. 204, 1775-1785 (2007).
24. Atarashi, K. et al. TREG induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 500, 232-236 (2013).
25. Atarashi, K. et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331, 337-341 (2011).
26. Smith, P. M. et al. The microbial metabolites, short-chain fatty acids, regulate colonic TREG cell homeostasis. Science 341, 569-573 (2013).
27. Furusawa, Y. et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504, 446-450 (2013).
28. Arpaia, N. et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504, 451-455 (2013).
29. Tanaka, S. et al. Graded attenuation of TCR signaling elicits distinct autoimmune diseases by altering thymic T cell selection and regulatory T cell function. J. Immunol. 185, 2295-2305 (2010).
30. Liu, W. H. et al. CD127 expression inversely correlates with Foxp3 and suppressive function of human CD4+ T REG cells. J. Exp. Med. 203, 1701-1711 (2006).
31. Seddiki, N. et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 203, 1693-1700 (2006).
32. Ukena, S. N. et al. Isolation strategies of regulatory T cells for clinical trials: Phenotype, function, stability, and expansion capacity. Exp. Hematol. 39, 1152-1160 (2011).
33. Walker, M. R. et al. Induction of Foxp3 and acquisition of T regulatory activity by stimulated human CD4+CD25-T cells. J. Clin. Invest. 112, 1437-1443 (2003).
34. Gavin, M. A. et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc. Natl Acad. Sci. USA 103, 6659-6664 (2006).
35. Tran, D. Q., Ramsey, H. & Shevach, E. M. Induction of FOXP3 expression in naive human CD4+FOXP3-T cells by T-cell receptor stimulation is transforming growth factor-beta-dependent but does not confer a regulatory phenotype. Blood 110, 2983-2990 (2007).
36. Wang, J., Ioan-Facsinay, A., Van der Voort, E. I. H., Huizinga, T. W. J. & Toes, R. E. M. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur. J. Immunol. 37, 129-138 (2007).
37. Allan, S. E. et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int. Immunol. 19, 345-354 (2007).
38. Milpied, P. et al. Neuropilin-1 is not a marker of human Foxp3+ TREG. Eur. J. Immunol. 39, 1466-1471 (2009).
39. Akimova, T., Beier, U. H., Wang, L., Levine, M. H. & Hancock, W. W. Helios expression is a marker of T cell activation and proliferation. PLoS ONE 6, e24226 (2011).
40. Himmel, M. E., MacDonald, K. G., Garcia, R. V., Steiner, T. S. & Levings, M. K. Helios+ and Helios-cells coexist within the natural FOXP3+ T regulatory cell subset in humans. J. Immunol. 190, 2001-2008 (2013).
41. Miyara, M. & Sakaguchi, S. Human Foxp3+CD4+ regulatory T cells: Their knowns and unknowns. Immunol. Cell Biol. 89, 346-351 (2011).
42. Miyara, M. et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the Foxp3 transcription factor. Immunity 30, 899-911 (2009).
43. Shevach, E. M. Mechanisms of Foxp3+ T regulatory cell-mediated suppression. Immunity 30, 636-645 (2009).
44. Sakaguchi, S., Wing, K., Onishi, Y., Prieto-Martin, P. & Yamaguchi, T. Regulatory T cells: How do they suppress immune responses? Int. Immunol. 21, 1105-1111 (2009).
45. Rubtsov, Y. P. et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 28, 546-558 (2008).
46. Collison, L. W. et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450, 566-569 (2007).
47. Li, M. O., Wan, Y. Y. & Flavell, R. A. T cell-produced transforming growth factor-β1 controls T cell tolerance and regulates TH1-and TH17-cell differentiation. Immunity 26, 579-591 (2007).
48. Takahashi, T. et al. Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192, 303-310 (2000).
49. Onishi, Y., Fehervari, Z., Yamaguchi, T. & Sakaguchi, S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc. Natl Acad. Sci. USA 105, 10113-10118 (2008).
50. Wing, K. et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322, 271-275 (2008).
51. Puccetti, P. & Grohmann, U. IDO and regulatory T cells: A role for reverse signalling and non-canonical NF-?B activation. Nat. Rev. Immunol. 7, 817-823 (2007).
52. Cobbold, S. P. et al. Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc. Natl Acad. Sci. USA 106, 12055-12060 (2009).
53. Takahashi, T. et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: Induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10, 1969-1980 (1998).
54. Thornton, A. M. & Shevach, E. M. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J. Immunol. 164, 183-190 (2000).
55. Sakaguchi, S., Vignali, D. A., Rudensky, A. Y., Niec, R. E. & Waldmann, H. The plasticity and stability of regulatory T cells. Nat. Rev. Immunol. 13, 461-467 (2013).
56. Zheng, Y. et al. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature 458, 351-356 (2009).
57. Chaudhry, A. et al. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 326, 986-991 (2009).
58. Zhou, X. et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 10, 1000-1007 (2009).
59. Bailey-Bucktrout, S. L. et al. Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity 39, 949-962 (2013).
60. Esposito, M. et al. IL-17-and IFN-?-secreting Foxp3+ T cells infiltrate the target tissue in experimental autoimmunity. J. Immunol. 185, 7467-7473 (2010).
61. Marson, A. et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 445, 931-935 (2007).
62. Zheng, Y. et al. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 445, 936-940 (2007).
63. Wu, Y. et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126, 375-387 (2006).
64. Ono, M. et al. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 446, 685-689 (2007).
65. Willerford, D. M. et al. Interleukin-2 receptor a chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3, 521-530 (1995).
66. Suzuki, H. et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor β. Science 268, 1472-1476 (1995).
67. Fontenot, J. D., Rasmussen, J. P., Gavin, M. A. & Rudensky, A. Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6, 1142-1151 (2005).
68. Burchill, M. A., Yang, J., Vogtenhuber, C., Blazar, B. R. & Farrar, M. A. IL-2 receptor β-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J. Immunol. 178, 280-290 (2007).
69. Caudy, A. A., Reddy, S. T., Chatila, T., Atkinson, J. P. & Verbsky, J. W. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J. Allergy Clin. Immunol. 119, 482-487 (2007).
70. Setoguchi, R., Hori, S., Takahashi, T. & Sakaguchi, S. Homeostatic maintenance of natural Foxp3+ CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201, 723-735 (2005).
71. Webster, K. E. et al. In vivo expansion of TREG cells with IL-2-mAb complexes: Induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J. Exp. Med. 206, 751-760 (2009).
72. Kawahata, K. et al. Generation of CD4+CD25+ regulatory T cells from autoreactive T cells simultaneously with their negative selection in the thymus and from nonautoreactive T cells by endogenous TCR expression. J. Immunol. 168, 4399-4405 (2002).
73. Jordan, M. S. et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat. Immunol. 2, 301-306 (2001).
74. Sakaguchi, S., Takahashi, T. & Nishizuka, Y. Study on cellular events in postthymectomy autoimmune oophoritis in mice. I. Requirement of Lyt-1 effector cells for oocytes damage after adoptive transfer. J. Exp. Med. 156, 1565-1576 (1982).
75. Itoh, M. et al. Thymus and autoimmunity: Production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J. Immunol. 162, 5317-5326 (1999).
76. Ehrenstein, M. R. et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFa therapy. J. Exp. Med. 200, 277-285 (2004).
77. Flores-Borja, F., Jury, E. C., Mauri, C. & Ehrenstein, M. R. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 105, 19396-19401 (2008).
78. Waterhouse, P. et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270, 985-988 (1995).
79. Tivol, E. A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541-547 (1995).
80. Cao, D. J., van Vollenhoven, R., Klareskog, L., Trollmo, C. & Malmström, V. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res. Ther. 6, R335-R346 (2004).
81. Liu, M. F., Wang, C. R., Fung, L. L., Lin, L. H. & Tsai, C. N. The presence of cytokine-suppressive CD4+CD25+ T cells in the peripheral blood and synovial fluid of patients with rheumatoid arthritis. Scand. J. Immunol. 62, 312-317 (2005).
82. Jiao, Z. et al. Accumulation of Foxp3-expressing CD4+CD25+ T cells with distinct chemokine receptors in synovial fluid of patients with active rheumatoid arthritis. Scand. J. Rheumatol. 36, 428-433 (2007).
83. van Amelsfort, J. M. R., Jacobs, K. M. G., Bijlsma, J. W. J., Lafeber, F. & Taams, L. S. CD4+CD25+ regulatory T cells in rheumatoid arthritis -Differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum. 50, 2775-2785 (2004).
84. Afzali, B. et al. CD161 expression characterizes a subpopulation of human regulatory T cells that produces IL-17 in a STAT3-dependent manner. Eur. J. Immunol. 43, 2043-2054 (2013).
85. Walter, G. J. et al. Interaction with activated monocytes enhances cytokine expression and suppressive activity of human CD4+CD45RO+CD25+CD127low regulatory T cells. Arthritis Rheum. 65, 627-638 (2013).
86. Herrath, J. et al. The inflammatory milieu in the rheumatic joint reduces regulatory T-cell function. Eur. J. Immunol. 41, 2279-2290 (2011).
87. Valencia, X. et al. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 108, 253-261 (2006).
88. Grinberg-Bleyer, Y. et al. Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J. Clin. Invest. 120, 4558-4568 (2010).
89. Ali, Y. & Shah, S. Infliximab-induced systemic lupus erythematosus. Ann. Intern. Med. 137, 625-626 (2002).
90. Favalli, E. G., Sinigaglia, L., Varenna, M. & Arnoldi, C. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 11, 753-755 (2002).
91. de Kleer, I. M. et al. CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J. Immunol. 172, 6435-6443 (2004).
92. Ruprecht, C. R. et al. Coexpression of CD25 and CD27 identifies Foxp3+ regulatory T cells in inflamed synovia. J. Exp. Med. 201, 1793-1803 (2005).
93. Haufe, S. et al. Impaired suppression of synovial fluid CD4+CD25-T cells from patients with juvenile idiopathic arthritis by CD4+CD25+ Treg cells. Arthritis Rheum. 63, 3153-3162 (2011).
94. Wehrens, E. J. et al. Functional human regulatory T cells fail to control autoimmune inflammation due to PKB/c-Akt hyperactivation in effector cells. Blood 118, 3538-3548 (2011).
95. de Kleer, I. et al. Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network. Blood 107, 1696-1702 (2006).
96. Kishimoto, T. Interleukin-6: From basic science to medicine-40 years in immunology. Annu. Rev. Immunol. 23, 1-21 (2005).
97. Feldmann, M. & Maini, S. R. Role of cytokines in rheumatoid arthritis: An education in pathophysiology and therapeutics. Immunol. Rev. 223, 7-19 (2008).
98. Pieper, J. et al. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol. 14, 34 (2013).
99. Roncador, G. et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur. J. Immunol. 35, 1681-1691 (2005).
100. Miyara, M. et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J. Immunol. 175, 8392-8400 (2005).
101. Venigalla, R. K. et al. Reduced CD4+, CD25-T cell sensitivity to the suppressive function of CD4+, CD25high, CD127 -/low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheum. 58, 2120-2130 (2008).
102. Solomou, E. E., Juang, Y. T., Gourley, M. F., Kammer, G. M. & Tsokos, G. C. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J. Immunol. 166, 4216-4222 (2001).
103. Stephens, L. A., Malpass, K. H. & Anderton, S. M. Curing CNS autoimmune disease with myelin-reactive Foxp3+ TREG. Eur. J. Immunol. 39, 1108-1117 (2009).
104. Tang, Q. et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 199, 1455-1465 (2004).
105. Tarbell, K. V. et al. Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J. Exp. Med. 204, 191-201 (2007).
106. Godebu, E., Summers-Torres, D., Lin, M. M., Baaten, B. J. & Bradley, L. M. Polyclonal adaptive regulatory CD4 cells that can reverse type I diabetes become oligoclonal long-term protective memory cells. J. Immunol. 181, 1798-1805 (2008).
107. McGeachy, M. J., Stephens, L. A. & Anderton, S. M. Natural recovery and protection from autoimmune encephalomyelitis: Contribution of CD4+CD25+ regulatory cells within the central nervous system. J. Immunol. 175, 3025-3032 (2005).
108. Korn, T. et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med. 13, 423-431 (2007).
109. Morgan, M. E. et al. Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis Rheum. 52, 2212-2221 (2005).
110. Zhou, X. et al. Cutting edge: All-trans retinoic acid sustains the stability and function of natural regulatory T cells in an inflammatory milieu. J. Immunol. 185, 2675-2679 (2010).
111. Kong, N. et al. Antigen-specific transforming growth factor beta-induced TREG cells, but not natural TREG cells, ameliorate autoimmune arthritis in mice by shifting the TH17/TREG cell balance from TH17 predominance to TREG cell predominance. Arthritis Rheum. 64, 2548-2558 (2012).
112. van Herwijnen, M. J. et al. Regulatory T cells that recognize a ubiquitous stress-inducible self-antigen are long-lived suppressors of autoimmune arthritis. Proc. Natl Acad. Sci. USA 109, 14134-14139 (2012).
113. Sakaguchi, N. et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 426, 454-460 (2003).
114. Humrich, J. Y. et al. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc. Natl Acad. Sci. USA 107, 204-209 (2010).
115. Weigert, O. et al. CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZB×NZW) F1 lupus mice. Arthritis Res. Ther. 15, R35 (2013).
116. Hasegawa, H. et al. Therapy for pneumonitis and sialadenitis by accumulation of CCR2-expressing CD4+CD25+ regulatory T cells in MRL/lpr mice. Arthritis Res. Ther. 9, R15 (2007).
117. Wright, G. P. et al. Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc. Natl Acad. Sci. USA 106, 19078-19083 (2009).
118. Zhang, J. L. et al. CD3 mAb treatment ameliorated the severity of the cGVHD-induced lupus nephritis in mice by up-regulation of Foxp3+ regulatory T cells in the target tissue: Kidney. Transpl. Immunol. 24, 17-25 (2010).
119. Battaglia, M., Stabilini, A. & Roncarolo, M. G. Rapamycin selectively expands CD4+CD25+Foxp3+ regulatory T cells. Blood 105, 4743-4748 (2005).
120. Battaglia, M. et al. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J. Immunol. 177, 8338-8347 (2006).
121. Strauss, L. et al. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J. Immunol. 178, 320-329 (2007).
122. Smolen, J. S., Aletaha, D. & Redlich, K. The pathogenesis of rheumatoid arthritis: New insights from old clinical data? Nat. Rev. Rheumatol. 8, 235-243 (2012).
123. Koreth, J. et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 365, 2055-2066 (2011).
124. Saadoun, D. et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. 365, 2067-2077 (2011).
125. Long, S. A. et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments TREGS yet transiently impairs beta-cell function. Diabetes 61, 2340-2348 (2012).
126. Hippen, K. L., Riley, J. L., June, C. H. & Blazar, B. R. Clinical perspectives for regulatory T cells in transplantation tolerance. Semin. Immunol. 23, 462-468 (2011).
127. Hoffmann, P. et al. Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 108, 4260-4267 (2006).
128. Benson, M. J., Pino-Lagos, K., Rosemblatt, M. & Noelle, R. J. All-trans retinoic acid mediates enhanced T REG cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J. Exp. Med. 204, 1765-1774 (2007).
129. Tao, R. et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 13, 1299-1307 (2007).
130. Polansky, J. K. et al. DNA methylation controls Foxp3 gene expression. Eur. J. Immunol. 38, 1654-1663 (2008).
131. Floess, S. et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 5, e38 (2007).
132. Kim, H. P. & Leonard, W. J. CREB/ATF-dependent T cell receptor-induced Foxp3 gene expression: A role for DNA methylation. J. Exp. Med. 204, 1543-1551 (2007).
133. Ohkura, N. et al. T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for TREG cell development. Immunity 37, 785-799 (2012).